CARAZOLOL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H22N2O2
Molecular Weight	298.3795
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NCC(O)COC1=CC=CC2=C1C3=CC=CC=C3N2

InChI

InChIKey=BQXQGZPYHWWCEB-UHFFFAOYSA-N

InChI=1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/41147 | http://www.inchem.org/documents/jecfa/jecmono/v43jec02.htm | http://europroxima.com/products/contaminants-and-residues/tranquilizers/carazol-elisa/

Carazolol is a beta1/beta2 adrenoreceptor blocking agent. Activity and safety of the drug were evaluated in clinical trials that were conducted in healthy subjects and in patients suffering from either chronic bronchitis or asthma. The drug, however, was not developed for human use. Instead, carazolol is used in to reduce stress in animals during transportation. In veterinary medicine, carazolol is given by intramuscular injection to pigs is indicated in stress-inducing situations. In cattle, carazolol is intended to be used for the prevention of shipment stress caused by transportation and formation of new herds.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 158 Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/41147	Antagonist 2778		0.15 nM [Ki]
Beta-2 adrenergic receptor 203 Target ID: P07550\|\|\|Q53GA6\|\|\|Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/41147	Antagonist 2778		0.15 nM [Ki]

PubMed

Title	Date	PubMed
Carazolol: a potent, selective beta 3-adrenoceptor agonist.	1995 Nov 30	8719421
Multiresidue analysis of tranquilizers and the beta-blocker Carazolol in meat by liquid chromatography/tandem mass spectrometry.	2001	11555876
Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence.	2001 May 5	11393694
Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems.	2002 Aug	12171563
Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization.	2004 Nov 26	15595665
Effect of carazolol on the oestrous behaviour and concentrations of luteinising hormone and steroids in lactating cows during the periovulatory period.	2007 Jun 9	17558028
Biochemistry. Signaling across the cell membrane.	2007 Nov 23	18033872
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.	2007 Nov 23	17962520
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.	2007 Nov 23	17962519
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS.	2008 Jul	18491081
Active state-like conformational elements in the beta2-AR and a photoactivated intermediate of rhodopsin identified by dynamic properties of GPCRs.	2008 Jul 15	18558776
Structure of a beta1-adrenergic G-protein-coupled receptor.	2008 Jul 24	18594507
Crystallizing thinking about the beta2-adrenergic receptor.	2008 May	18239031
On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.	2008 May 22	18442228
Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.	2008 Oct 15	18829308
Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.	2008 Oct 21	18821775
Virtual screening of GPCRs: an in silico chemogenomics approach.	2008 Sep 6	18775075
Computing highly correlated positions using mutual information and graph theory for G protein-coupled receptors.	2009	19262747
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry.	2009 Apr 1	19286028
Chiral separation of beta-adrenergic blockers on CelluCoat column by HPLC.	2009 Apr 30	19203609
Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.	2009 Jul-Aug	19353579
Allosteric modulation of adenosine receptors.	2009 Mar	18615273
Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.	2009 May	19148767
Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer.	2009 Nov 4	19763081
FoldGPCR: structure prediction protocol for the transmembrane domain of G protein-coupled receptors from class A.	2010 Aug 1	20544957
Dynamics of the beta2-adrenergic G-protein coupled receptor revealed by hydrogen-deuterium exchange.	2010 Feb 1	20058880
Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach.	2010 Mar 16	20233425

Name

Type

Language

CARAZOLOL

Official Name

English

SUACRON

Brand Name

English

carazolol [INN]

Common Name

English

CARAZOLOL [MART.]

Common Name

English

CONDUCTON

Brand Name

English

BM-51052

Code

English

1-(CARBAZOL-4-YLOXY)-3-(ISOPROPYLAMINO)-2-PROPANOL

Systematic Name

English

Carazolol [WHO-DD]

Common Name

English

BM 51052

Code

English

CARAZOLOL [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC07AA90